Automatically translated.View original post

💊 Pfizer Stocks (PFE) - Dividend Line Health Stocks

Pfizer (PFE), one of the world's major pharmaceutical companies, is undergoing an eye-catching adaptation after the success of COVID-19 vaccine and drug products that helped make a fortune, but still faces the challenges of competition and the expiration of pharmaceutical patents.

📈 Outstanding results.

In the most recent quarter, Pfizer reported earnings exceeding! EPS of $0.78, ðŸ’ĩ higher than analysts expected, leading the company to raise its full-year earnings estimates as well, a positive sign that investors should keep an eye on 👀

💉 sales are growing even past the peak.

Major products like the Comirnaty vaccine and Paxlovid drugs have also continued to grow in sales, 📊 along with other drugs such as Vyndaqel and Eliquis growing steadily. Pfizer also reinforces its business by acquiring Seagen in the cancer line. ðŸŽŊ is an interesting long-term strategy.

💰 High Dividend Steady Profit

Investors who like to receive dividends must be interested because Pfizer has a dividend yield of 6.7% 📈, significantly higher than the market average, and has increased dividends for 15 years, 🏆 and has enough cash coming in to make the returns stable and sustainable.

⚠ Risks to watch out for

Despite its good looks, Pfizer has faced challenges from the expiration of several drug patents 🔒, which allow competitors to compete in generic drugs, including a potential future decline in demand for the COVID-19 vaccine. 📉

📝 Summary

Pfizer is an ideal stock for investors looking for stability and growth in the long run ðŸŒą, albeit with some risks, but with a strong expansion and dividend strategy, PFE remains an attractive option in the health stock sector. 💊

It is also the number 2 sweetheart dividend line stock.

# Stock# Stock America# Dividend stock # Invest shares

2025/9/4 Edited to

... Read moreāļŦāļĨāļēāļĒāļ„āļ™āđ€āļŦāđ‡āļ™āļ•āļąāļ§āļĒāđˆāļ­ â€œPFE” āđāļĨāđ‰āļ§āļŠāļ‡āļŠāļąāļĒāļ§āđˆāļē āļŦāļļāđ‰āļ™ Pfizer (PFE) āļ—āļģāļ˜āļļāļĢāļāļīāļˆāļ­āļ°āđ„āļĢ? āļˆāļēāļāļ—āļĩāđˆāļœāļĄāļ•āļīāļ”āļ•āļēāļĄāļšāļĢāļīāļĐāļąāļ—āļ™āļĩāđ‰ āļˆāļ°āļĄāļ­āļ‡ Pfizer āđ€āļ›āđ‡āļ™ â€œāļšāļĢāļīāļĐāļąāļ—āļĒāļēāļĢāļ°āļ”āļąāļšāđ‚āļĨāļâ€ āļ—āļĩāđˆāļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļāļĄāļēāļˆāļēāļāļāļēāļĢāļ§āļīāļˆāļąāļĒ āļžāļąāļ’āļ™āļē āļœāļĨāļīāļ• āđāļĨāļ°āļˆāļģāļŦāļ™āđˆāļēāļĒāļĒāļē/āļ§āļąāļ„āļ‹āļĩāļ™ āļ„āļĢāļ­āļšāļ„āļĨāļļāļĄāļ—āļąāđ‰āļ‡āļĒāļēāļĢāļąāļāļĐāļēāđ‚āļĢāļ„āđ€āļĢāļ·āđ‰āļ­āļĢāļąāļ‡ āļĒāļēāđ€āļ‰āļžāļēāļ°āļ—āļēāļ‡ āđāļĨāļ°āļ§āļąāļ„āļ‹āļĩāļ™ āđ„āļĄāđˆāđ„āļ”āđ‰āļžāļķāđˆāļ‡āđāļ„āđˆāļāļĢāļ°āđāļŠ COVID-19 āļ­āļĒāđˆāļēāļ‡āđ€āļ”āļĩāļĒāļ§ (āđāļĄāđ‰āļŠāđˆāļ§āļ‡āļ™āļąāđ‰āļ™āļĢāļēāļĒāđ„āļ”āđ‰āļˆāļ°āļžāļļāđˆāļ‡āļĄāļēāļ) āļ āļēāļžāļĢāļ§āļĄāļ˜āļļāļĢāļāļīāļˆāļ‚āļ­āļ‡ PFE āđāļšāđˆāļ‡āđƒāļŦāđ‰āđ€āļ‚āđ‰āļēāđƒāļˆāļ‡āđˆāļēāļĒ āđ† āđ„āļ”āđ‰āļ›āļĢāļ°āļĄāļēāļ“āļ™āļĩāđ‰ 1) āļĒāļēāđāļĨāļ°āļ§āļąāļ„āļ‹āļĩāļ™āļ—āļĩāđˆāļ‚āļēāļĒāđƒāļŦāđ‰āđ‚āļĢāļ‡āļžāļĒāļēāļšāļēāļĨ/āļ„āļĨāļīāļ™āļīāļāđāļĨāļ°āļ āļēāļ„āļĢāļąāļāļ—āļąāđˆāļ§āđ‚āļĨāļ 2) āļāļĨāļļāđˆāļĄāļĒāļēāļ—āļĩāđˆāđ€āļ›āđ‡āļ™ â€œāļšāļĨāđ‡āļ­āļāļšāļąāļŠāđ€āļ•āļ­āļĢāđŒâ€ āļŦāļĢāļ·āļ­āļ‚āļēāļĒāđ„āļ”āđ‰āļ•āđˆāļ­āđ€āļ™āļ·āđˆāļ­āļ‡āļŦāļĨāļēāļĒāļ›āļĩ āđ€āļŠāđˆāļ™ āļĒāļēāđ‚āļĢāļ„āļŦāļąāļ§āđƒāļˆ/āļŦāļĨāļ­āļ”āđ€āļĨāļ·āļ­āļ” āļĒāļēāļĄāļ°āđ€āļĢāđ‡āļ‡ āļĒāļēāļŦāļēāļĒāļēāļāļšāļēāļ‡āļāļĨāļļāđˆāļĄ 3) āļāļēāļĢāđ€āļ•āļīāļšāđ‚āļ•āļˆāļēāļāļāļēāļĢāļ‹āļ·āđ‰āļ­āļāļīāļˆāļāļēāļĢ (āđ€āļŠāđˆāļ™āļ”āļĩāļĨāļāļąāđˆāļ‡āļĄāļ°āđ€āļĢāđ‡āļ‡āļ—āļĩāđˆāļ•āļĨāļēāļ”āļˆāļąāļšāļ•āļē) āđ€āļžāļ·āđˆāļ­āđ€āļ•āļīāļĄāļ—āđˆāļ­āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒ (pipeline) āđƒāļ™āļ­āļ™āļēāļ„āļ• āļ–āđ‰āļēāļ–āļēāļĄāļ§āđˆāļē “āļ•āļ­āļ™āļ™āļĩāđ‰ PFE āļ™āđˆāļēāļŠāļ™āđƒāļˆāļ•āļĢāļ‡āđ„āļŦāļ™â€ āļŠāļģāļŦāļĢāļąāļšāļŠāļēāļĒāļ›āļąāļ™āļœāļĨ āļˆāļļāļ”āļ—āļĩāđˆāļœāļĄāļŠāļ­āļšāļ„āļ·āļ­ Pfizer āļĄāļĩāļ›āļĢāļ°āļ§āļąāļ•āļīāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāļŠāļĄāđˆāļģāđ€āļŠāļĄāļ­ āđāļĨāļ°āļˆāļēāļāļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļŦāđ‡āļ™āļāļąāļ™āļšāđˆāļ­āļĒ āđ† āļ„āļ·āļ­āļ­āļąāļ•āļĢāļēāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāļ­āļĒāļđāđˆāđāļ–āļ§ āđ† 6–7% āđāļĨāļ°āļˆāđˆāļēāļĒāļ—āļļāļ 3 āđ€āļ”āļ·āļ­āļ™ (quarterly) āļ—āļģāđƒāļŦāđ‰āđ€āļŦāļĄāļēāļ°āļāļąāļšāļ„āļ™āļ—āļĩāđˆāļ•āđ‰āļ­āļ‡āļāļēāļĢāļāļĢāļ°āđāļŠāđ€āļ‡āļīāļ™āļŠāļ”āļŠāļĄāđˆāļģāđ€āļŠāļĄāļ­ āđ‚āļ”āļĒāđƒāļ™āļšāļēāļ‡āļŠāđˆāļ§āļ‡āļĒāļąāļ‡āđ€āļŦāđ‡āļ™āļāļēāļĢāļ—āļĒāļ­āļĒāđ€āļžāļīāđˆāļĄāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāļ•āđˆāļ­āđ€āļ™āļ·āđˆāļ­āļ‡āļŦāļĨāļēāļĒāļ›āļĩāļ”āđ‰āļ§āļĒ āļ­āļĩāļāđ€āļĢāļ·āđˆāļ­āļ‡āļ—āļĩāđˆāļĄāļ·āļ­āđƒāļŦāļĄāđˆāļĄāļąāļāļžāļĨāļēāļ”āļ„āļ·āļ­ â€œāļĒāļĩāļĨāļ”āđŒāļŠāļđāļ‡āđ€āļžāļĢāļēāļ°āļĢāļēāļ„āļēāļĨāļ‡â€ āļāđ‡āđ€āļ›āđ‡āļ™āđ„āļ›āđ„āļ”āđ‰āđ€āļŦāļĄāļ·āļ­āļ™āļāļąāļ™ āđ€āļŠāđˆāļ™ āļŦāļēāļāļĢāļēāļ„āļē PFE āđāļ–āļ§ āđ† 24–25 USD āđāļĨāđ‰āļ§āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāļ•āđˆāļ­āļ›āļĩāļ›āļĢāļ°āļĄāļēāļ“ 1.7 USD āļĒāļĩāļĨāļ”āđŒāļĄāļąāļ™āļˆāļ°āļ”āļđāļŠāļđāļ‡āļ—āļąāļ™āļ—āļĩ āļ”āļąāļ‡āļ™āļąāđ‰āļ™āļœāļĄāļˆāļ°āļ”āļđāđ€āļžāļīāđˆāļĄāļ§āđˆāļē āļāļĢāļ°āđāļŠāđ€āļ‡āļīāļ™āļŠāļ”āļĒāļąāļ‡āļžāļ­āļˆāđˆāļēāļĒāđ„āļŦāļĄ āļŦāļ™āļĩāđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™āđ„āļŦāļĄ āđāļĨāļ°āļšāļĢāļīāļĐāļąāļ—āļĄāļĩāđāļœāļ™āļŸāļ·āđ‰āļ™āļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļ‡āļĒāļ­āļ”āļ‚āļēāļĒāļ§āļąāļ„āļ‹āļĩāļ™/āļĒāļēāļŠāđˆāļ§āļ‡ COVID āļĨāļ”āļĨāļ‡āļ­āļĒāđˆāļēāļ‡āđ„āļĢ āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āļŦāļĨāļąāļāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļĒāļēāļ­āļĒāđˆāļēāļ‡ Pfizer āļ—āļĩāđˆāļ„āļ§āļĢāļĢāļđāđ‰āļāđˆāļ­āļ™āļĨāļ‡āļ—āļļāļ™ - āļŠāļīāļ—āļ˜āļīāļšāļąāļ•āļĢāļŦāļĄāļ”āļ­āļēāļĒāļļ (patent cliff): āļžāļ­āļĒāļēāļŦāļĨāļąāļāļŦāļĄāļ”āļŠāļīāļ—āļ˜āļīāđŒ āļ„āļđāđˆāđāļ‚āđˆāļ‡āļ—āļģāļĒāļēāļŠāļēāļĄāļąāļāđ„āļ”āđ‰ āļĢāļēāļĒāđ„āļ”āđ‰āļ­āļēāļˆāļŦāļēāļĒāđ€āļĢāđ‡āļ§ - āļ„āļ§āļēāļĄāđ„āļĄāđˆāđāļ™āđˆāļ™āļ­āļ™āļ‚āļ­āļ‡ R&D: āļ§āļīāļˆāļąāļĒāļĒāļēāđāļžāļ‡āđāļĨāļ°āđƒāļŠāđ‰āđ€āļ§āļĨāļēāļ™āļēāļ™ āđ„āļĄāđˆāđƒāļŠāđˆāļ—āļļāļāļ•āļąāļ§āļˆāļ°āļŠāļģāđ€āļĢāđ‡āļˆ - āļĢāļēāļĒāđ„āļ”āđ‰āļœāļąāļ™āļœāļ§āļ™āļ•āļēāļĄāļĢāļ­āļšāđ‚āļĢāļ„/āļ™āđ‚āļĒāļšāļēāļĒāļĢāļąāļ/āļāļēāļĢāļ•āļąāđ‰āļ‡āļĢāļēāļ„āļēāļĒāļē āļ–āđ‰āļēāļ„āļļāļ“āļ„āđ‰āļ™āļŦāļē “āļŦāļļāđ‰āļ™pfe” āđ€āļžāļĢāļēāļ°āļ­āļĒāļēāļāđ€āļĢāļīāđˆāļĄāļĨāļ‡āļ—āļļāļ™āđāļšāļšāļ›āļĨāļ­āļ”āļ āļąāļĒāļ‚āļķāđ‰āļ™ āļœāļĄāđāļ™āļ°āļ™āļģāđƒāļŦāđ‰āļ•āļąāđ‰āļ‡āđ€āļŠāđ‡āļāļĨāļīāļŠāļ•āđŒāļŠāļąāđ‰āļ™ āđ† āļāđˆāļ­āļ™āļāļ”āļ‹āļ·āđ‰āļ­: āļ”āļđāļ§āđˆāļēāđ€āļĢāļēāļ‹āļ·āđ‰āļ­āđ€āļžāļĢāļēāļ°āļ›āļąāļ™āļœāļĨāļŦāļĢāļ·āļ­āđ€āļžāļĢāļēāļ°āļŦāļ§āļąāļ‡āļĢāļēāļ„āļēāđ€āļ”āđ‰āļ‡, āļĢāļąāļšāļ„āļ§āļēāļĄāļœāļąāļ™āļœāļ§āļ™āđ„āļ”āđ‰āđāļ„āđˆāđ„āļŦāļ™, āđāļĨāļ°āļāļĢāļ°āļˆāļēāļĒāļžāļ­āļĢāđŒāļ•āđ„āļ›āļŦāļļāđ‰āļ™āļŠāļļāļ‚āļ āļēāļžāļ•āļąāļ§āļ­āļ·āđˆāļ™āļ”āđ‰āļ§āļĒāļŦāļĢāļ·āļ­āļĒāļąāļ‡ āļŠāļļāļ”āļ—āđ‰āļēāļĒ PFE āđ€āļ›āđ‡āļ™āļŦāļļāđ‰āļ™āđƒāļŦāļāđˆāļ—āļĩāđˆāļĄāļĩāļˆāļļāļ”āđāļ‚āđ‡āļ‡āđ€āļĢāļ·āđˆāļ­āļ‡āđāļšāļĢāļ™āļ”āđŒāđāļĨāļ°āļ‚āļ™āļēāļ”āļ˜āļļāļĢāļāļīāļˆ āđāļ•āđˆāļāđ‡āļĒāļąāļ‡āļ•āđ‰āļ­āļ‡āļ•āļēāļĄāļ‚āđˆāļēāļ§āđ€āļĢāļ·āđˆāļ­āļ‡āļĒāļēāđƒāļŦāļĄāđˆāđāļĨāļ°āļŠāļīāļ—āļ˜āļīāļšāļąāļ•āļĢāđ€āļ›āđ‡āļ™āļĢāļ°āļĒāļ° āđ† āļ„āļĢāļąāļš